Magazine Article | July 1, 2022

Biopharma In China: The Emerging Global Force Of Domestic Suppliers

Source: Life Science Leader

By Vicky Xia and Leo Yang

Quite a few Chinese biopharma companies are shifting their purchase of supplies from global multinational corporation (MNC) vendors to domestic vendors for their clinical stage projects via process changes. Many say domestic substitution would be more common if the National Medical Products Administration (NMPA) gets more lenient with process changes.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: